QUOIN PHARMACEUTICALS LT-ADR (QNRX) Stock Overview
NASDAQ:QNRX - US74907L4095 - ADR
QNRX Key Statistics, Chart & Performance
The current stock price of QNRX is 7.38 USD. In the past month the price decreased by -3.47%. In the past year, price decreased by -66.32%.
QNRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.65 | 367.55B | ||
| AMGN | AMGEN INC | 13.2 | 155.03B | ||
| GILD | GILEAD SCIENCES INC | 14.72 | 141.35B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.97 | 99.76B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.86 | 62.21B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.53B | ||
| ARGX | ARGENX SE - ADR | 76.37 | 43.33B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.06 | 35.68B | ||
| INSM | INSMED INC | N/A | 28.44B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.76B | ||
| NTRA | NATERA INC | N/A | 22.38B | ||
| BIIB | BIOGEN INC | 8.52 | 19.99B |
Related stock screener links
About QNRX
Company Profile
Quoin Pharmaceuticals Ltd is a IL-based company operating in Biotechnology industry. Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
Company Info
QUOIN PHARMACEUTICALS LT-ADR
23 Hata'as Street
Kfar Saba IL
CEO: Shai Yarkoni
Employees: 3
Phone: 97299741444
QUOIN PHARMACEUTICALS LT-ADR / QNRX FAQ
What is the stock price of QUOIN PHARMACEUTICALS LT-ADR today?
The current stock price of QNRX is 7.38 USD. The price increased by 0.07% in the last trading session.
What is the ticker symbol for QUOIN PHARMACEUTICALS LT-ADR stock?
The exchange symbol of QUOIN PHARMACEUTICALS LT-ADR is QNRX and it is listed on the Nasdaq exchange.
On which exchange is QNRX stock listed?
QNRX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for QUOIN PHARMACEUTICALS LT-ADR stock?
8 analysts have analysed QNRX and the average price target is 28.05 USD. This implies a price increase of 280.08% is expected in the next year compared to the current price of 7.38. Check the QUOIN PHARMACEUTICALS LT-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is QUOIN PHARMACEUTICALS LT-ADR worth?
QUOIN PHARMACEUTICALS LT-ADR (QNRX) has a market capitalization of 4.34M USD. This makes QNRX a Nano Cap stock.
How many employees does QUOIN PHARMACEUTICALS LT-ADR have?
QUOIN PHARMACEUTICALS LT-ADR (QNRX) currently has 3 employees.
What are the support and resistance levels for QUOIN PHARMACEUTICALS LT-ADR (QNRX) stock?
QUOIN PHARMACEUTICALS LT-ADR (QNRX) has a support level at 7.26 and a resistance level at 7.49. Check the full technical report for a detailed analysis of QNRX support and resistance levels.
Should I buy QUOIN PHARMACEUTICALS LT-ADR (QNRX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of QNRX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of QNRX, evaluating the profitability, health, valuation and growth aspects
- QUOIN PHARMACEUTICALS LT-ADR (QNRX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- QUOIN PHARMACEUTICALS LT-ADR (QNRX) Sales and EPS estimates to see what analysts future expectations are.
- QUOIN PHARMACEUTICALS LT-ADR (QNRX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- QUOIN PHARMACEUTICALS LT-ADR (QNRX) Insider and Institutional Ownership to learn about the owners and their transactions.
- QUOIN PHARMACEUTICALS LT-ADR (QNRX) Stock Chart to make your own analysis
- QUOIN PHARMACEUTICALS LT-ADR (QNRX) Latest news and press-releases to stay up to date.
Does QUOIN PHARMACEUTICALS LT-ADR (QNRX) stock pay dividends?
QNRX does not pay a dividend.
When does QUOIN PHARMACEUTICALS LT-ADR (QNRX) report earnings?
QUOIN PHARMACEUTICALS LT-ADR (QNRX) will report earnings on 2025-11-05.
What is the Price/Earnings (PE) ratio of QUOIN PHARMACEUTICALS LT-ADR (QNRX)?
QUOIN PHARMACEUTICALS LT-ADR (QNRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-41.48).
What is the Short Interest ratio of QUOIN PHARMACEUTICALS LT-ADR (QNRX) stock?
The outstanding short interest for QUOIN PHARMACEUTICALS LT-ADR (QNRX) is 1.64% of its float. Check the ownership tab for more information on the QNRX short interest.
QNRX Technical Analysis
QNRX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to QNRX. QNRX has a bad profitability rating. Also its financial health evaluation is rather negative.
QNRX Financial Highlights
Over the last trailing twelve months QNRX reported a non-GAAP Earnings per Share(EPS) of -41.48. The EPS increased by 78.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -80.64% | ||
| ROE | -176.3% | ||
| Debt/Equity | 0.47 |
QNRX Forecast & Estimates
8 analysts have analysed QNRX and the average price target is 28.05 USD. This implies a price increase of 280.08% is expected in the next year compared to the current price of 7.38.